CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $8.55B, above the global median of $1.15B
- PositionOperating margin is 84.5%, higher than 95% of its Biotechnology peers (median 13.5%)
- Interpretations4 currently firing — 4
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
57.08BCNY8.55B · vs all stocks (USD)
Trailing P/E
9.62xvs Biotechnology peers
Revenue (TTM)
8.01BCNY1.20B · vs all stocks (USD)
Profit Margin
72.71%vs Biotechnology peers
Beta
0.4580xvs all stocks
52-Week Change
7.87%vs all stocks
Forward Annual Dividend Yield
0.00%vs all stocks
Market Capitalization
57.08BCNY8.55B · vs all stocks (USD)
Enterprise Value
48.91BCNY7.33B · vs all stocks (USD)
Trailing P/E
9.62xvs Biotechnology peers
Forward P/E
67.28xvs Biotechnology peers
Price to Sales (TTM)
6.71xvs Biotechnology peers
Price to Book (MRQ)
6.36xvs Biotechnology peers
Enterprise to Revenue
6.11xvs Biotechnology peers
Enterprise to EBITDA
9.51xvs Biotechnology peers
Profit Margin
72.71%vs Biotechnology peers
Operating Margin
84.45%vs Biotechnology peers
Return on Assets (TTM)
39.01%vs Biotechnology peers
Return on Equity (TTM)
109.10%vs Biotechnology peers
Revenue (TTM)
8.01BCNY1.20B · vs all stocks (USD)
Revenue per Share (TTM)
14.31CNYUpdated Oct 24, 2026Quarterly Revenue Growth
808.60%vs Biotechnology peers
Gross Profit (TTM)
7.51BCNY1.13B · vs all stocks (USD)
EBITDA (TTM)
454.98MCNY68.19M · vs all stocks (USD)
Net Income (TTM)
5.82BCNY872.47M · vs all stocks (USD)
Operating Cash Flow (TTM)
4.51BCNY676.26M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
3.60BCNY539.87M · vs all stocks (USD)
Forward Annual Dividend Yield
0.00%vs all stocks
Trailing Annual Dividend Rate
0.00CNYUpdated Oct 24, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
3.24BCNYFY2025 · Dec 31, 2025Cost of Goods Sold
425.50MCNYFY2025 · Dec 31, 2025Gross Profit
2.82BCNYFY2025 · Dec 31, 2025Operating Income
156.35MCNY23.43M · vs all stocks (USD)
Pre-tax Income
710.40MCNYFY2025 · Dec 31, 2025Income Tax Expense
749.00KCNYFY2025 · Dec 31, 2025Net Income
709.65MCNYFY2025 · Dec 31, 2025EBIT
780.57MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
454.98MCNYFY2025 · Dec 31, 2025Research & Development
1.22BCNYFY2025 · Dec 31, 2025Selling, General & Administrative
1.47BCNYFY2025 · Dec 31, 2025Non-operating Interest Income
4.59MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
70.17MCNYFY2025 · Dec 31, 2025EPS (Basic)
1.29CNYFY2025 · Dec 31, 2025EPS (Diluted)
1.29CNYFY2025 · Dec 31, 2025Basic Shares Outstanding
549.76MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
549.76MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
710.40MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
233.97MCNYFY2025 · Dec 31, 2025Free Cash Flow
36.34MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
1.15BCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
710.40MCNYFY2025 · Dec 31, 2025Stock-based Compensation
33.90MCNYFY2025 · Dec 31, 2025Other Non-cash Items
66.24MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
-568.59MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-7.97MCNYFY2025 · Dec 31, 2025Capital Expenditures
-197.64MCNYFY2025 · Dec 31, 2025Net Intangibles (CF)
-240.00KCNYFY2025 · Dec 31, 2025Net Acquisitions
-13.10MCNYFY2025 · Dec 31, 2025Purchase of Investments
-2.16BCNYFY2025 · Dec 31, 2025Sale of Investments
2.16BCNYFY2025 · Dec 31, 2025Other Investing Activity
610.00KCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-204.80MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
2.03BCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-2.12BCNYFY2025 · Dec 31, 2025Other Financing Charges
-40.00MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
697.52MCNYFY2025 · Dec 31, 2025Shares Outstanding
563.71MSharesUpdated Oct 24, 2026Float Shares
341.96MSharesUpdated Oct 24, 2026% Held by Insiders
54.12%vs all stocks
% Held by Institutions
11.64%vs all stocks
Total Cash (MRQ)
5.14BCNY770.92M · vs all stocks (USD)
Total Cash per Share (MRQ)
9.27CNYUpdated Oct 24, 2026Total Debt (MRQ)
311.02MCNY46.61M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.0374xvs Biotechnology peers
Current Ratio (MRQ)
4.86xvs Biotechnology peers
Book Value per Share (MRQ)
14.97CNYUpdated Oct 24, 2026Total Assets
7.25BCNY1.09B · vs all stocks (USD)
Total Current Assets
3.98BCNYFY2025 · Dec 31, 2025Total Liabilities
3.64BCNYFY2025 · Dec 31, 2025Total Non-current Assets
3.27BCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
846.92MCNYFY2025 · Dec 31, 2025Total Current Liabilities
2.79BCNYFY2025 · Dec 31, 2025Cash
1.15BCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
1.15BCNYFY2025 · Dec 31, 2025Other Short-term Investments
1.22BCNYFY2025 · Dec 31, 2025Accounts Receivable
422.77MCNYFY2025 · Dec 31, 2025Inventory
661.49MCNYFY2025 · Dec 31, 2025Accounts Payable
285.85MCNYFY2025 · Dec 31, 2025Short-term Debt
1.45BCNYFY2025 · Dec 31, 2025Other Current Liabilities
38.67MCNYFY2025 · Dec 31, 2025Long-term Debt
751.90MCNYFY2025 · Dec 31, 2025Common Stock (Book)
563.71MCNYFY2025 · Dec 31, 2025Retained Earnings
-3.61BCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
3.61BCNY540.85M · vs all stocks (USD)
Treasury Stock
237.19MCNYFY2025 · Dec 31, 202552-Week Low
75.03CNYUpdated Oct 24, 202652-Week High
157.80CNYUpdated Oct 24, 202652-Week Change
7.87%vs all stocks
Beta
0.4580xvs all stocks
50-Day MA
116.91CNYUpdated Oct 24, 2026200-Day MA
117.93CNYUpdated Oct 24, 2026Avg 10-Day Volume
4.44MSharesUpdated Oct 24, 2026Avg 30-Day Volume
5.26MSharesUpdated Oct 24, 2026Diluted EPS (TTM)
9.89CNYUpdated Oct 24, 20264 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsHow does this company use capital?
Diagnostic
High ROE With Large Non-Operating Gap and Elevated-Margin-With-Deceleration
Return on equity reads high, with a large gap between pretax and operating income.
Reads
Industry-Benchmarked ROA and Margin Elevated
Returns and margins have sat in the top of its industry across five years.
Reads
Revenue Growing With Receivables Growing
Revenue has risen three years, and what customers owe has risen with it.
Reads
Minimal Tax and Interest Drag
Almost nothing is lost between its operating profit and its net income.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Operating margin is 84.5%, higher than 95% of its Biotechnology peers (median 13.5%)Significant
Operating margin: 0.84Industry median: 0.14Industry P95: 0.58Peers compared: 22.00
Profit margin is 72.7%, higher than 95% of its Biotechnology peers (median 13.1%)Significant
Profit margin: 0.73Industry median: 0.13Industry P95: 0.36Peers compared: 22.00
Return on equity is 109.1%, higher than 95% of its Biotechnology peers (median 6.6%)Significant
Return on equity: 1.09Industry median: 0.07Industry P95: 0.40Peers compared: 22.00
Return on assets is 39%, higher than 95% of its Biotechnology peers (median 5.1%)Significant
Return on assets: 0.39Industry median: 0.05Industry P95: 0.18Peers compared: 22.00
P/E ratio is 9.62×, lower than 95% of its Biotechnology peers (median 40.53×)Notable
P/E ratio: 9.62Industry median: 40.53Industry P5: 13.93Peers compared: 22.00
Financial Health
Low earnings qualitySignificant
Earnings Quality Score: -0.82
Altman Z-Score 9.71: safe zoneNotable
Altman Z-Score: 9.71
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $8.55B, above the global median of $1.15BNotable
Market cap (USD): 8,554,949,952.599Global Median: 1,150,342,212.262
Revenue is $1.2B, above the global median of $559.35MNotable
Revenue (USD): 1,199,917,863.532Global Median: 559,350,010.583
Levered free cash flow is $539.87M, above the global median of $18.98MNotable
Levered free cash flow (USD): 539,871,085.071Global Median: 18,979,762.15
Companies that share the same coordination system — how they create, deliver, or capture value.
Vaxcyte, Inc.
Tier 1ProductionApproval-Gated PipelineRule
TG Therapeutics, Inc.
Tier 1ProductionApproval-Gated PipelineRule
ImmunityBio, Inc.
Tier 1ProductionApproval-Gated PipelineRule
Cytokinetics, Incorporated
Tier 1ProductionApproval-Gated PipelineRuleRisk
Crinetics Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
Shanghai Fosun Pharmaceutical Group Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Glaukos Corporation
Tier 1ProductionApproval-Gated PipelineRule
Protagonist Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Kymera Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Arrowhead Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Sk Biopharmaceuticals Co., Ltd.
3 interpretationsIndustry-Benchmarked ROA and Margin ElevatedRevenue Growing With Receivables GrowingMinimal Tax and Interest Drag
argenx SE
3 interpretationsIndustry-Benchmarked ROA and Margin ElevatedRevenue Growing With Receivables GrowingMinimal Tax and Interest Drag
Aryt Industries Ltd.
3 interpretationsHigh ROE With Large Non-Operating Gap and Elevated-Margin-With-DecelerationIndustry-Benchmarked ROA and Margin ElevatedRevenue Growing With Receivables Growing